Rationale for Adjunctive Treatment Targeting Multiple Mechanisms in Schizophrenia
The Journal of Clinical Psychiatry · 19.08.2024 · 85 (3)
DOI: 10.4088/jcp.23nr15240 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Psychiatry, online erschienen am 19.08.2024. Verfasst von Bruce J Kinon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Karuna Therapeutics, Boston, Massachusetts. Hauptthemen laut MEDLINE: Schizophrenia, Antipsychotic Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref).
Abstract (Originalsprache)
Importance: Schizophrenia is a complex syndrome with taxing symptoms and for which treatment challenges remain. Current dopamine D2 receptor-blocking antipsychotics have well-known limitations, including ineffectively treating across all symptom domains and generating common side effects such as motor disturbances, weight gain, and metabolic dysfunction. New approaches are sorely needed to address the continued unmet treatment needs for individuals living with schizophrenia. Observations: Although current antipsychotic drugs indicated for the treatment of schizophrenia interact with various neurotransmitter receptors, they all commonly act as dopamine D2 receptor antagonists or partial agonists. While antipsychotics primarily relieve positive symptoms, residual positive symptoms are still common, and management of negative symptoms and cognitive impairment remains an unmet need. Problematic side effects are common with current agents and can contribute to nonadherence. In addition to alterations in dopaminergic pathways, increasing evidence indicates that the pathophysiology of schizophrenia also includes dysfunction in other neurotransmitter systems including glutamate, acetylcholine, serotonin, and γ-aminobutyric acid. While the pathophysiology of schizophrenia is complex, treatments with novel pharmacologic actions that target these systems are of interest as adjunctive treatment for individuals with schizophrenia. Conclusion and Relevance: An unmet need exists for effective treatment of all the core symptoms of schizophrenia. Novel antipsychotics with a nondopaminergic mechanism of action may be useful candidates for antipsychotic adjunctive treatment in people with schizophrenia who are showing inadequate responses, treatment resistance, or low tolerance to dopamine D2 receptor-blocking antipsychotics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Karuna Therapeutics, Boston, Massachusetts.
- Corresponding Author: Bruce J. Kinon, MD (bjkinon@sbcglobal.net), c/o Alicia Meli, MS, Bristol Myers Squibb Corporate Headquarters, Route 206 & Province Line Road, Princeton, NJ 08543.
- Department of Psychiatry and Psychotherapy, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany.
- Department of Psychiatry, University of Texas Southwestern Medical School, Dallas, Texas.
- Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana.
- Bristol Myers Squibb, Princeton, New Jersey.
Zitieren
APA
Kinon, B. J., Leucht, S., Tamminga, C., Breier, A., Marcus, R., & Paul, S. M. (2024). Rationale for Adjunctive Treatment Targeting Multiple Mechanisms in Schizophrenia. The Journal of Clinical Psychiatry, 85(3). https://doi.org/10.4088/jcp.23nr15240
Vancouver
Kinon BJ, Leucht S, Tamminga C, Breier A, Marcus R, Paul SM. Rationale for Adjunctive Treatment Targeting Multiple Mechanisms in Schizophrenia. The Journal of Clinical Psychiatry. 2024;85(3). doi:10.4088/jcp.23nr15240
BibTeX
@article{Kinon2024,
author = {Kinon, Bruce J and Leucht, Stefan and Tamminga, Carol and Breier, Alan and Marcus, Ronald and Paul, Steven M},
title = {Rationale for Adjunctive Treatment Targeting Multiple Mechanisms in Schizophrenia},
journal = {The Journal of Clinical Psychiatry},
year = {2024},
volume = {85},
number = {3},
doi = {10.4088/jcp.23nr15240}
}
EUVIMED